Pfizer

Yahoo Finance • 7 hours ago

Notable healthcare headlines for the week: Novo Nordisk, Bristol Myers Squibb and J&J in focus

Tom Werner Wall Street's major averages plummeted on Friday after U.S. President Donald Trump threatened higher tariffs to China, saying it had "become very hostile" sending letters to other countries wanting to "impose export controls."... Full story

Yahoo Finance • yesterday

AstraZeneca Strikes Drug-Pricing Deal With Trump Administration

The agreement, which entails offering “most-favored nation” drug pricing, follows Pfizer’s deal to reduce prices for its drugs sold in the Medicaid program and through a new direct-purchasing service to be branded TrumpRx. Continue Readin... Full story

Yahoo Finance • yesterday

AstraZeneca Cuts Discounted Drug Pricing Deal With the White House. The Stock Is Rising.

AstraZeneca on Friday became the second big drugmaker after Pfizer to cut a pricing deal with the White House, announcing an agreement alongside President Donald Trump at a late afternoon press conference. AstraZeneca stock was up 1.6% in... Full story

Yahoo Finance • yesterday

AstraZeneca to Ink Drug-Pricing Deal With Trump Administration

AstraZeneca is the latest major drugmaker to strike a deal with the Trump administration on lowering U.S. drug prices, according to a person familiar with the matter. The agreement and its details, which have yet to be disclosed, follow la... Full story

Yahoo Finance • yesterday

AstraZeneca to follow Pfizer lead in making drug price deal with Trump - report

[AstraZeneca company office building] Robert Way * President Trump at 5p ET Friday will say that AstraZeneca has made a deal with the Trump administration to cut the prices of its drugs, following in the footsteps of Pfizer's (PFE) agre... Full story

Yahoo Finance • 2 days ago

Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly

By Bhanvi Satija and Maggie Fick LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to lower... Full story

Yahoo Finance • 2 days ago

Sandoz granted tentative approval for generic of Pfizer's Inlyta

[White medicine pill tablet isolated on white background] Kwangmoozaa * The U.S. FDA has given tentative approval to Sandoz (OTCQX:SDZNY [https://seekingalpha.com/symbol/SDZNY]) for a generic version of Pfizer's (NYSE:PFE [https://seeki... Full story

Yahoo Finance • 2 days ago

Pfizer declares $0.43 dividend

* Pfizer (NYSE:PFE [https://seekingalpha.com/symbol/PFE]) declares $0.43/share quarterly dividend [https://seekingalpha.com/pr/20261584-pfizer-declares-fourth-quarter-2025-dividend], in line with previous. * Forward yield [https://seek... Full story

Yahoo Finance • 3 days ago

Next CDC AdCom meeting on vaccines delayed

[Centers for disease control and prevention sign] sshepard The Centers for Disease Control and Prevention (CDC) has postponed an October meeting of its Advisory Committee on Immunization Practices (ACIP), an expert panel whose views are c... Full story

Yahoo Finance • 3 days ago

Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab

Company Logo The bispecific antibodies market presents key opportunities in oncology, autoimmune, and infectious diseases, driven by rapid technological advancements and strategic collaborations. Regional manufacturing and diverse supplie... Full story

Yahoo Finance • 3 days ago

Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion

Company Logo The Duchenne Muscular Dystrophy Drugs Market presents opportunities in advanced genetic therapies, digital health, and adaptive models amid rising global demand. Strategic alliances, resilient supply chains, and localized str... Full story

Yahoo Finance • 3 days ago

Nuvation Bio Inc. (NUVB): A Bull Case Theory

We came across a bullish thesis on Nuvation Bio Inc. on wallstreetbets subreddit by asagi_lumina. In this article, we will summarize the bulls’ thesis on NUVB. Nuvation Bio Inc.'s share was trading at $3.2200 as of September 23rd.AbCellera... Full story

Yahoo Finance • 4 days ago

Should You Buy Pfizer (PFE) Before a Breakout Begins?

We recently published Top 10 Trending Stocks as Famous Billionaire Predicts Massive AI Stock Rally Before Bubble Burst. Pfizer Inc (NYSE:PFE) is one of the trending stocks. Analysts are getting excited about major healthcare stocks like P... Full story

Yahoo Finance • 4 days ago

Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead

Key Points CRISPR Therapeutics and BioNTech have climbed along with many of their peers over the past week. Both are innovative biotechs with catalysts that could drive their stocks higher in the next few years. 10 stocks we like better t... Full story

Yahoo Finance • 4 days ago

Families of Trump and commerce secretary stand to benefit from U.S. drug overhaul: WSJ

[President Trump Signs Executive Order At The White House] Andrew Harnik/Getty Images News Family members of President Donald Trump and Commerce Secretary Howard Lutnick are set to profit as the U.S. government steps up its efforts to low... Full story

Yahoo Finance • 4 days ago

Mikael Dolsten, M.D., Ph.D., Joins TRIO Pharmaceuticals as Chairman

Mikael Dolsten, M.D., Ph.D., chairman of TRIO Pharmaceuticals SAN CARLOS, Calif., October 08, 2025--(BUSINESS WIRE)--TRIO Pharmaceuticals, a biotechnology company advancing novel multi-functional antibody treatments for cancers with high... Full story

Yahoo Finance • 4 days ago

Former Top FDA Official, Forced Out by Kennedy, Lands at Eli Lilly

Dr. Peter Marks, the top Food and Drug Administration official whose forced resignation earlier this year set off a panic among biotech investors, is now an executive at Eli Lilly the company said on Tuesday. Marks stepped down as the chie... Full story

Yahoo Finance • 5 days ago

Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care

HYDERABAD, India, Oct. 7, 2025 /PRNewswire/ -- The Rare Disease Therapeutics Market is experiencing an unprecedented wave of innovation, driven by gene therapies, RNA-based treatments, enzyme replacement therapies (ERTs), and targeted biol... Full story

Yahoo Finance • 5 days ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)

BALA CYNWYD, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 5 days ago

The No. 1 Investing Mistake to Avoid As Washington Grinds to a Halt

Key Points Investing is often driven by emotions. Big news events can lead to a rise in emotional decision-making. Don't fall into the emotional trap that Wall Street often leans into when exciting stories pop up. 10 stocks we like better... Full story